Katiyar S K, Edlind T D
MCP Hahnemann University, Philadelphia, Pennsylvania 19129, USA.
Med Mycol. 2001 Feb;39(1):109-16. doi: 10.1080/mmy.39.1.109.116.
Infections with Candida krusei have increased in recent years as a consequence of its intrinsic resistance to fluconazole, an antifungal azole widely used in immunocompromised individuals to suppress infections due to azole-susceptible C. albicans. One established mechanism for azole resistance is drug efflux by ATP binding cassette (ABC) transporters. Since these transporters recognize structurally diverse drugs, their overexpression can lead to multidrug resistance (MDR). To identify C. krusei genes potentially involved in azole resistance, PCR was performed with primers corresponding to conserved sequences of MDR-related ABC transporters from other fungi. Two genes, ABC1 and ABC2, were identified; Southern blots suggested that both have one or two related gene copies in the C. krusei genome. ABC1 RNA was constitutively expressed at low levels in log phase cells while ABC2 RNA was undetectable. However, both genes were upregulated as cultures approached stationary phase, and this upregulation was correlated with decreased susceptibility to the lethal activity of the azole derivative miconazole. Furthermore, ABC1 was upregulated following brief treatment of C. krusei with miconazole and clotrimazole (but not other azoles), and the unrelated compounds albendazole and cycloheximide. The latter two compounds antagonized fluconazole activity versus C. krusei, supporting a role for the ABC1 transporter in azole efflux. Finally, miconazole-resistant mutants selected in vitro demonstrated increased constitutive expression of ABC1. Based on these expression data, genetic and functional characterization of the ABC1 transporter to directly test its role in C. krusei azole resistance would appear to be warranted.
近年来,克鲁斯念珠菌感染有所增加,这是由于其对氟康唑具有固有耐药性。氟康唑是一种广泛用于免疫功能低下个体以抑制由对唑类敏感的白色念珠菌引起的感染的抗真菌唑类药物。一种已确定的唑类耐药机制是通过ATP结合盒(ABC)转运蛋白进行药物外排。由于这些转运蛋白能识别结构多样的药物,它们的过度表达可导致多药耐药(MDR)。为了鉴定克鲁斯念珠菌中可能与唑类耐药有关的基因,使用与其他真菌中与MDR相关的ABC转运蛋白保守序列相对应的引物进行了PCR。鉴定出了两个基因,ABC1和ABC2;Southern印迹表明,这两个基因在克鲁斯念珠菌基因组中都有一个或两个相关基因拷贝。ABC1 RNA在对数期细胞中以低水平组成性表达,而ABC2 RNA未检测到。然而,随着培养物接近稳定期,这两个基因均上调,并且这种上调与对唑类衍生物咪康唑致死活性的敏感性降低相关。此外,用咪康唑和克霉唑(但不是其他唑类)以及不相关的化合物阿苯达唑和环己酰亚胺对克鲁斯念珠菌进行短暂处理后,ABC1上调。后两种化合物拮抗氟康唑对克鲁斯念珠菌的活性,支持ABC1转运蛋白在唑类外排中的作用。最后,体外选择的咪康唑抗性突变体显示ABC1的组成性表达增加。基于这些表达数据,对ABC1转运蛋白进行遗传和功能表征以直接测试其在克鲁斯念珠菌唑类耐药中的作用似乎是有必要的。